
|Videos|April 15, 2020
A 59-Year Old Woman With Stage IIIC Ovarian Cancer
A 59-Year Old Woman With Stage IIIC Ovarian Cancer
Advertisement
Case: A 59-Year Old Female With Stage IIIC Ovarian Cancer
Initial Presentation
- A 59-year old female presented with new onset early satiety, abdominal bloating and discomfort
- PMH: unremarkable, postmenopausal
- SH: schoolteacher; no tobacco, alcohol or drug use
- PE: abdominal distention, left lower quadrant tender on palpation, shifting dullness noted on percussion
Clinical work-up
- Pelvic exam with transvaginal ultrasound showed a left ovarian mass
- Chest/abdomen/pelvis CT with contrast revealed a left adnexal 4.8-cm mass, extension to liver capsule without parenchymal involvement; retroperitoneal lymph node involvement and ascites noted; no pleural effusion
- Lymph node, adnexal mass biopsy, and paracentesis (2000 cc) cytology confirmed high-grade epithelial ovarian cancer
- Diagnosis: high-grade epithelial ovarian cancer; stage IIIC T3cN1M0
- Germline/molecular testing showed HRD-,BRCA1/2wildtype
- CA-125, 385 U/mL
- ECOG PS 1
Treatment
- Patient underwent TAH/BSO, lymph node dissection, with optimal debulking; R0
- IP/IV paclitaxel/carboplatin + bevacizumab every 3 weeks for 6 cycles
- Followed by bevacizumab for 6 more cycles
- Complete response; post treatment CA125, 48 U/mL
Follow-up
- 3-months CA-125, 30 U/mL
- Chest/abdomen/pelvis CT showed no gross pelvic masses or nodes
- Pelvic exam, unremarkable
- ECOG PS 0
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































